Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

Upworthy

Published

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity developed in collaboration with Pleco Therapeutics Liège, Belgium – 16 January 2024, 07:30PM CET – Non-Regulated…

#usfda #aml #belgium #hyl #fda #plecotherapeuticsbv #stijnvanrompay #ivotimmermans #plecotherapeutics #globaldata

Full Article